INmune Bio

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell INmune Bio and other ETFs, options, and stocks.

About INMB

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. Its product pipeline includes INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. 

CEO
David J. Moss
CEODavid J. Moss
Employees
22
Employees22
Headquarters
Boca Raton, Florida
HeadquartersBoca Raton, Florida
Founded
2015
Founded2015
Employees
22
Employees22

INMB Key Statistics

Market cap
59.15M
Market cap59.15M
Price-Earnings ratio
-1.04
Price-Earnings ratio-1.04
Dividend yield
Dividend yield
Average volume
653.57K
Average volume653.57K
High today
$2.35
High today$2.35
Low today
$2.10
Low today$2.10
Open price
$2.14
Open price$2.14
Volume
784.43K
Volume784.43K
52 Week high
$11.64
52 Week high$11.64
52 Week low
$1.38
52 Week low$1.38

Stock Snapshot

INmune Bio(INMB) stock is priced at $2.26, giving the company a market capitalization of 59.15M. It carries a P/E multiple of -1.04.

On 2025-12-11, INmune Bio(INMB) stock moved within a range of $2.10 to $2.35. With shares now at $2.26, the stock is trading +7.6% above its intraday low and -3.8% below the session's peak.

Trading volume for INmune Bio(INMB) stock has reached 784.43K, versus its average volume of 653.57K.

The stock's 52-week range extends from a low of $1.38 to a high of $11.64.

The stock's 52-week range extends from a low of $1.38 to a high of $11.64.

INMB News

Simply Wall St 2d
Can INmune Bio Afford To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com...

Can INmune Bio Afford To Invest In Growth?
TipRanks 5d
Inmune Bio Unveils Promising Alzheimer’s Trial Data

TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRank...

TipRanks 6d
INmune Bio publishes study on INmune’s CORDStrom platform

INmune Bio (INMB) announces a recently published overview of future applications and research areas for mesenchymal stromal cell therapies, such as INmune’s COR...

People also own

Based on the portfolios of people who own INMB. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.